nach oben

Medical Oncology

Erschienen in:

01.05.2014 | Original Paper

Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma

verfasst von: Zheng Fang, Lei Lu, Zhiqiang Tian, Kunlun Luo

Erschienen in: Medical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have confirmed the role of phosphorylated form of 4E-binding protein 1 (p-4E-BP1) as a good candidate tumor biomarker. The aim of this study was to investigate p-4E-BP1 expression status in hilar cholangiocarcinoma (HCCA) specimens and to clarify its clinical significance. Tissue microarray containing tumor specimens obtained from 61 patients with HCCA were constructed. p-4E-BP1 was investigated by immunohistochemical studies. High/moderate expression p-4E-BP1 was observed in 57.4 % (35/61) primary cancer specimens. Overexpression of p-4E-BP1 protein was associated with poor differentiation and regional lymph node metastasis. Survival analysis and Cox proportional hazards model revealed that p-4E-BP1 overexpression was an independent factor in predicting recurrence-free survival and overall survival for HCCA patients, apart from tumor invasion and complete resection. P-4E-BP1 was highly expressed in HCCA. Overexpressed p-4E-BP1 might be a novel biomarker to predict the clinical outcome of patients with resected HCCA.

Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:33–42.PubMedCrossRef

Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kawasaki R. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci. 2010;17:455–62.PubMedCrossRef

Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, y Cajal SR. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 2007;67:7551–5.PubMedCrossRef

Magagnin MG, van den Beucken T, Sergeant K, Lambin P, Koritzinsky M, Devreese B, Wouters BG. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics. 2008;8:1019–28.PubMedCrossRef

Barnhart BC, Lam JC, Young RM, Houghton PJ, Keith B, Simon MC. Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol Ther. 2008;7:1441–9.PubMedCentralPubMedCrossRef

Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J, y Cajal SR. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 2007;13:81–9.PubMedCrossRef

Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, y Cajal SR. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006;107:1801–11.PubMedCrossRef

Benavente S, Vergés R, Hermosilla E, Fumanal V, Casanova N, García A, Ramón Y, Cajal S, Giralt J. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:1316–22.PubMedCrossRef

Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, y Cajal SR. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol. 2009;40:1418–26.PubMedCrossRef

10.

Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY, Tseng CK, Chang HK, Hsueh C. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch. 2011;458:171–8.PubMedCrossRef

11.

Jiao X, Pan J, Qian J, Luo T, Wang Z, Yu G, Wang J. Overexpression of p-4ebp1 in Chinese gastric cancer patients and its correlation with prognosis. Hepatogastroenterology. 2013;60:921–6.PubMed

12.

Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–9.PubMedCrossRef

13.

Song H, Xu B, Yi J. Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients. J Exp Clin Cancer Res. 2012;31:35.PubMedCentralPubMedCrossRef

14.

Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, Nagino M. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17:449–54.PubMedCrossRef

15.

Ramacciato G, Nigri G, Bellagamba R, Petrucciani N, Ravaioli M, Cescon M, Del Gaudio M, Ercolani G, Di Benedetto F, Cautero N, Quintini C, Cucchetti A, Lauro A, Miller C, Pinna MD. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg. 2010;76:1260–8.PubMed

16.

Otani K, Chijiiwa K, Kai M, Ohuchida J, Nagano M, Tsuchiya K, Kondo K. Outcome of surgical treatment of hilar cholangiocarcinoma. J Gastrointest Surg. 2008;12:1033–40.PubMedCrossRef

17.

Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, Vernadakis S, Trarbach T, Paul A, Kaiser GM. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res. 2010;15:356–7.CrossRef

18.

Munoz-Garrido P, de Barrena MGF, Hijona E, Carracedo M, Marín JJ, Bujanda L, Banales JM. MicroRNAs in biliary diseases. World J Gastroenterol. 2012;18:6189–96.PubMedCentralPubMedCrossRef

19.

Heesom KJ, Gampel A, Mellor H, Denton RM. Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol. 2001;11:1374–9.PubMedCrossRef

20.

Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphory-lation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 2004;64:8639–42.PubMedCrossRef

21.

Averous J, Proud CG. When translation meets transforma-tion: the mTOR story. Oncogene. 2006;25:6423–35.PubMedCrossRef

22.

Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67:3431–40.PubMedCrossRef

23.

O’Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res. 2009;15:2872–8.PubMedCentralPubMedCrossRef

24.

Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 2004;5:553–63.PubMedCrossRef

25.

Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun. 2004;313:429–36.PubMedCrossRef

26.

Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94:195–9.PubMedCentralPubMedCrossRef

Titel: Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma
verfasst von: Zheng Fang
Lei Lu
Zhiqiang Tian
Kunlun Luo
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0940-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients

Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study

A clinical analysis of 37 cases with lymphoepithelial carcinoma of the major salivary gland treated by surgical resection and postoperative radiotherapy: a single institution study

On the status of β-cell dysfunction and insulin resistance of breast cancer patient without history of diabetes after systemic treatment

c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer

No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie